Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS1819-SD dose-escalation study for exocrine pancreatic insufficiency due to chronic pancreatitis or distal pancreatectomy
ACTRN12616000962437Phase 2Recruiting
- Sponsor
- Syneos Health
- Start
- Jan 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of adrulipase alfa in exocrine pancreatic insufficiency (EPI) and chronic pancreatitis (CP), sponsored by Syneos Health. Primary endpoint: Safety of escalating doses of MS1819-SD. Started Jan 2017; status: recruiting.
02
Drugs
adrulipase alfa
03
Conditions
exocrine pancreatic insufficiency (EPI)chronic pancreatitis (CP)
Beyond the preview
Go deeper on ACTRN12616000962437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000962437.